NewsRoom Articles - Page 53 of 218

MondayJan 22, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment

Significant improvements in both vision and cognition, sustained over three years, were reported with CNM-Au8 treatment in results from the long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis Michael Barnett, a key clinical advisor, hailed the results, observed long term and over and above background therapy. as “unprecedented” A drug that may halt MS disease progression or improve function on top of standard-of-care MS therapies would represent a significant milestone in drug development for this disease Clene will present the full clinical results for the LTE at the ninth annual Americas Committee for…

FridayJan 19, 2024 1:32 pm

Study Suggests Pediatric Autism Could Be Linked to Umbilical Cord Lipid Levels at Birth

New research has looked into the link between the cord blood lipid levels, autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) symptomatology. ASD and ADHD are neurodevelopmental disorders that affect the central nervous system, which is responsible for language, movement, memory, focusing and social skills. It is common knowledge that early-life risk factors such as maternal inflammation and contaminant chemicals impact neurodevelopmental conditions, including ADHD and ASD. These conditions can cause changes in serological lipids, which make up about 60% of brain weight and are necessary for neurodevelopment. For their research, the investigators utilized lipidomic analysis data from the Barwon…

ThursdayJan 18, 2024 1:42 pm

Scientists Discover Alzheimer’s Can Be Categorized into Five Subtypes

Researchers have determined that there are different types of Alzheimer’s after they studied proteins found in cerebrospinal fluid. Alzheimer’s is a common form of dementia. This progressive illness often starts with memory loss and causes patients to lose their ability to speak in its later stages. This greatly impacts their ability to engage in daily activities. An abnormal protein build-up, which results in the death of nerve cells, is said to be the primary cause of this progressive illness. The death of these cells in turn causes the loss of functions they provide, which robs patients of their ability to…

WednesdayJan 17, 2024 3:15 pm

Ancient DNA Suggests Origins of Multiple Sclerosis in EU

A massive cache of ancient genomes has helped researchers trace the origins of a wide variety of the genetic traits that occur in modern Europeans. According to the ancient DNA, characteristics such as an increased risk of developing multiple sclerosis may have reached Europe more than 45,000 years ago in the genomes of people who migrated to the European continent in three distinct waves. The research findings suggest that differences in the dispersal patterns of ancient migrants may have resulted in some of the regional variation seen in specific traits, contradicting the theory that genetic differences could have have occurred…

TuesdayJan 16, 2024 11:15 am

InvestorBrandNetwork Highlights PaxMedica Inc.’s (NASDAQ: PXMD) Video Release on Transformative ASD Study

In a significant development for the neurological disorder community, PaxMedica (NASDAQ: PXMD) has released an insightful video detailing the outcomes of its Phase 2 study on Autism Spectrum Disorder (“ASD”), initially published in the Annals of General Psychiatry. This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD. The study, a comprehensive 14-week randomized, double-blind, placebo-controlled trial, enrolled 52 boys aged 4–15 years with moderate to severe ASD. Focused on evaluating the efficacy and safety of…

FridayJan 12, 2024 12:30 pm

Fruit Fly Study Opens Door to Novel Immunotherapy Approach Against Cancer

Researchers from UC Santa Barbara recently solved a mystery that had been unanswered for more than two decades and potentially opened a door to the development of novel immunotherapy protocols against cancer. After examining evidence from fruit flies, mice and humans over several decades, the scientists uncovered the fact that cannibalistic cells may be responsible for a rare human immunodeficiency. The study’s senior author, Professor Denise Montell, stated that the research used basic cell biology and human pathology to pave the way for a new cancer therapy. Montell is a UC Santa Barbara Duggan professor as well as a distinguished…

ThursdayJan 11, 2024 10:44 am

TikTok Wants to Hit $17.5B in Online US Sales in 2024

TikTok plans to expand its operations in the American e-commerce sector to roughly $17.5 billion this year. TikTok, a product by ByteDance Limited, announced its goal in recent meetings focused on its progress. The achievement of this objective would put TikTok at a better strategic position to acquire an even larger share of the e-commerce market, which is currently held by Amazon.com Inc. Unlike strategies employed by peers such as Shein and Temu, TikTok shop centers blend convenient shopping experiences with online entertainment in the United States. This strategy encourages consumers to make impulse purchases. TikTok hopes to attract more…

WednesdayJan 10, 2024 3:48 pm

Multidisciplinary Consortium Sets Sights on Developing AI to Detect Gliomas

A new multidisciplinary consortium is combining knowledge from several different disciplines to develop new methods for diagnosing and treating gliomas. Comprised of Sweden’s Umeå University and Umeå University Hospital and PSE Data Security from Switzerland, the consortium will amalgamate knowledge on data security, brain tumors and machine learning to potentially create new and more effective diagnostic and treatment techniques for the brain tumor. Glioma is a relatively common type of brain tumor that occurs in roughly 33% of brain tumor patients and affects around 19,000 new patients in the United States every year. Members of the consortium signed a collaboration…

TuesdayJan 09, 2024 2:54 pm

New Compound Promises Greater Efficacy Against Pain, Has No Side Effects

A newly found compound, CBD3063, has shown that it can be significantly effective at treating chronic pain in animal studies with barely any side effects. Scientists discovered the compound after screening a whopping 27 million potential drugs extensively. CBD3063 works by targeting the Cav2.2 calcium channel in a way researchers have never seen before and has shown that it can surpass existing pain-relief medications such as gabapentin in terms of efficacy. The research team published its findings in the “Proceedings of the National Academy of Sciences” (PNAS) journal. Chronic pain is an often-debilitating condition that affects 51.6 million (20.9%) of…

MondayJan 08, 2024 11:15 am

Astrotech Corp. (NASDAQ: ASTC) Announces New Mass Spectrometry Technology Application for Chemical Manufacturing and Introduces the Pro-Control Subsidiary

Astrotech’s newest subsidiary, Pro-Control, will use the company’s mass spectrometer technology to improve purity, and yields of distilled chemicals Pro-Control delivers value by improving lost yields and delivering found profits directly to the bottom line with little, which the company believes will lead to an overall increase in profitability Astrotech believes that the Pro-Control MVP has the ability to routinely improve yields from 20% to 30% The company is introducing its proprietary ATi Mass Spectrometer Technology into the vast chemical manufacturing and process control markets Astrotech (NASDAQ: ASTC), is an instrumentation company that is focused on commercializing its proprietary ATi…